Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
Recruiting now NCT05328505
Run by University Health Network, Toronto · for 18 and older · Men
What this study is about
This is a Phase II prospective single-arm trial that is recruiting 80 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET. Participants of this study will receive molecular imaging informed radiation dose escalation to site of recurrent disease and de-escalation to uninvolved areas. Participants will be follow-up as per standard of care up to 5 years post-treatment.
Who can join (things the study team will check)
✅ You may be able to join if…
- Men older than 18 years old.
- Histologically proven initial diagnosis of adenocarcinoma prostate cancer.
- Previous radical prostatectomy.
- Biochemical relapse with local or regional recurrence proven on PSMA PET.
- Five or less positive nodes on the PSMA PET.
- ECOG 0-1
🚫 You may not be able to join if…
- Presence of para-aortic lymph nodes or distant metastasis.
- Chronic pelvic inflammatory disease.
- Contraindication for radiation treatment.
- Previous radiation treatment within the pelvis
Where this trial is running
- London Health Sciences Centre, London, Ontario, Canada
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
Who to contact
Andrew McPartlin, MD · 416-946-4501 · andrew.mcpartlin@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05328505.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.